HC Wainwright sets USD 25 target for Monte Rosa stock

Published on 10/05/2026 at 06:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For Monte Rosa stock, GFORCE-1 enrolled 108 subjects and cut hsCRP 85 percent. Gout testing is expected in Q4 2026 or Q1 2027, with initial data in H2 2027.

GLUE, US61225M1027, Illustration mit AI erstellt.

HC Wainwright initiated coverage of Monte Rosa Therapeutics with a Buy rating and set a USD 25 price target on October 1, 2026, according to Yahoo Finance. The call arrived as Monte Rosa reported Phase 1 results for MRT-8102, with the company stock later showing a USD 887.0 million market capitalization as of October 5, 2026.

Phase 1 data set the catalyst

Monte Rosa's October 1, 2026 filing said the GFORCE-1 study enrolled 108 obese subjects with elevated cardiovascular disease risk. Participants received once-daily doses of 5 mg, 20 mg or 40 mg, or placebo, for four weeks of treatment followed by four weeks of safety follow-up, according to the StockTitan filing page.

The key comparison was biological rather than financial. MRT-8102 produced median NEK7 degradation of 80 to 90 percent across dose levels, while median hsCRP fell 85 percent and lipoprotein(a) fell 24 percent after four weeks. Treatment-emergent adverse events occurred in 33 percent of MRT-8102 participants versus 30 percent for placebo, and no serious adverse events were reported, the filing said.

Phase 2 timetable adds milestones

Monte Rosa expects to begin GEMINI-1, a Phase 2 gout study, in Q4 2026 or Q1 2027, with initial data expected in H2 2027. GFORCE-2, a Phase 2b study in stable coronary artery disease, and GALAXY-1 in hidradenitis suppurativa are expected to begin in H1 2027, according to the October 1, 2026 filing.

The timetable gives the GFORCE-1 readout a measurable follow-through: the company is moving from a 108-subject biomarker study toward multiple disease-specific Phase 2 programs. The principal execution issue is that the proposed six-month GFORCE-2 design remains subject to regulatory feedback and additional long-term toxicology work, as described in the filing.

Market value and analyst target

HC Wainwright's USD 25 target stands 138.10 percent above the USD 10.50 last quote on Nasdaq at 4:00 p.m. ET on October 2, 2026. That quote was 6.75 percent below the USD 11.26 prior close, while the 52-week range stood at USD 7.24 to USD 25.77 as of October 5, 2026.

Monte Rosa's clinical strategy now rests on whether the biomarker reductions translate into controlled Phase 2 evidence. The near-term calendar therefore combines the planned gout start in Q4 2026 or Q1 2027 with the broader H1 2027 cardiovascular and inflammatory program timetable.